MBIO
MUSTANG BIO, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.37
−0.90%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +2.4%
- EBIT
- +2.5%
- EPS
- +65.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +87.4%
- EBIT
- +85.0%
- Net income
- +87.8%
- EPS
- +84.8%
- Free cash flow
- +53.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026